StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright lowered their price target on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a report on Wednesday, August 7th.
View Our Latest Report on Minerva Neurosciences
Minerva Neurosciences Trading Up 0.7 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- How to Use the MarketBeat Excel Dividend Calculator
- Walmart Stock: Buy the Rip or Wait for the Dip?
- Consumer Discretionary Stocks Explained
- 3 Stocks to Buy for a Soft Landing, If There Is One
- The Significance of Brokerage Rankings in Stock Selection
- Why You Shouldn’t Count Out Tencent Music Stock After Earnings
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.